Reishi mushroom supplement for adults with fatty liver disease linked to metabolic problems
Tests reishi mushroom powder against placebo in adults with metabolic dysfunction-associated fatty liver disease.
Plain-language title generated from the registry record
Registry title: Hepatoprotective Effects of Reishi Mushroom- (Ganoderma Lucidum) Among Metabolic Dysfunction-associated Fatty Liver Disease Patients
Key facts
- Where
- Lahore, PakistanSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 35 and 65 years old?
Source: NCT07534241, who can take part
Where in Pakistan
- Sana NoreenLahore, PakistanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Lahore
- Trial code
- NCT07534241
- Record updated
- 30 July 2026
- Original description
This 12-week RCT investigates the hepatoprotective and immunomodulatory effects of Ganoderma lucidum combined with a probiotic-rich diet in adults with MAFLD, assessing liver enzymes, lipid profile, inflammation, gut microbiota, and oxidative stress.Read full original descriptionShow less
Hepatoprotective Effects of Reishi Mushroom- (Ganoderma Lucidum) Among Metabolic Dysfunction-associated Fatty Liver Disease Patients
This 12-week RCT investigates the hepatoprotective and immunomodulatory effects of Ganoderma lucidum combined with a probiotic-rich diet in adults with MAFLD, assessing liver enzymes, lipid profile, inflammation, gut microbiota, and oxidative stress.
Findings are expected to show dose-dependent improvements in hepatic fat, insulin resistance, and inflammatory markers, potentially reducing reliance on pharmacotherapy in
Inclusion: Adults aged 35-65 years; BMI between 18.5 and 30 kg/m²; Complete Blood Count test ranges, WBC < 4,000-11,000 cells/µL, RBC Men < 4.5-6.0 / Women 4.0-5.5 million/µL, Hemoglobin: Men < 13.5-17.5 / Women 12.0-15.5 g/dL, Platelets < 150,000-450,000 cells/µL; Lipid profile test markers (elevated LDL, total cholesterol, or triglycerides less than 150mg/dL high 200-499mg/dL and 500 mg/dL are above high; Liver function test markers, ALT > 56 U/L, AST>40 U/L, ALP>147 UL; Inflammatory markers: CRP >3 mg/L, - IL-6 ≥3 pg/mL, TNF-α ≥8 pg/mL; Elevated blood sugar levels, or hyperglycemia, refer to a typically above 126 mg/dL, fasting or 200 mg/dL post-meal.
Exclusion: ● Diagnosed with severe cardiovascular disease, liver failure, or renal impairment; Pregnant or lactating women; Individuals currently on statins, ezetimibe, PCSK9 inhibitors, or any other lipid-lowering therapy; Allergic to mushrooms; Diagnosed with celiac disease or other chronic gastrointestinal disorders (e.g., Crohn's disease, ulcerative colitis); History of malignancy; Participation in another clinical trial within the last 3 months.